Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Clinical Outcomes of Lumbar Degenerative Disc Disease in Active-Duty U.S. Service Personnel

This study has been terminated.
(Terminated due to enrollment failure)
Information provided by:
Synthes USA HQ, Inc. Identifier:
First received: December 8, 2009
Last updated: July 1, 2011
Last verified: July 2011

December 8, 2009
July 1, 2011
April 2010
March 2011   (final data collection date for primary outcome measure)
The primary endpoint of this study is the assessment of the mean Oswestry Low Back Pain Disability Questionnaire (ODI) improvement at the twelve (12) month and twenty-four (24) month follow-up visits relative to baseline. [ Time Frame: 24 months ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01028300 on Archive Site
  • Time to return to active duty [ Time Frame: 24 months ] [ Designated as safety issue: No ]
  • No re-operations, revisions, removals or supplemental fixation [ Time Frame: 24 months ] [ Designated as safety issue: No ]
  • No implant related complications [ Time Frame: 24 months ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
Clinical Outcomes of Lumbar Degenerative Disc Disease in Active-Duty U.S. Service Personnel
Clinical Outcomes of Lumbar Degenerative Disc Disease Treated Operatively in Active-Duty U.S. Service Personnel With Lumbar Total Disc Replacement

Degenerative disc disease (DDD) refers to a syndrome in which a degenerating disc causes chronic back pain, significantly impacting an individual's ability to function. The condition is most commonly diagnosed in the lumbosacral spinal segments L3-S1. The condition often starts with an injury to the disc space. The injury weakens the disc and creates excessive motion at the corresponding vertebral level. Over time, the segmental instability and associated neurological compromise combined with ongoing inflammatory processes that occur in and around the disc produce low back pain. The reparative processes in the disc are poor, thus the painful symptoms can become chronic.

Premature degeneration at adjacent levels of the spine remains one of the more vexing problems facing spinal surgeons when advising relatively young people to consider lumbar fusion surgery. Stopping the motion changes the mechanics of the back (which is designed for motion and flexibility) and results in the transfer of the loads and stresses to the adjacent vertebral segments. It is therefore intuitive to pursue total disc replacement, which allows for the treatment of pain due to DDD while re-establishing motion and stability, load distribution, and restoring the disc height, as an alternative to spinal fusion surgery.

The study hypothesis is that military personnel receiving Total Disc Replacement will return to the same level of active duty performance as at the time of their most recent successful physical readiness test.

Not Provided
Not Provided
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Degenerative Disc Disease
Device: ProDisc™-L Total Disc Replacement (TDR)
The design is based on a ball and socket articulation, one surface being metal and the other an ultra-high molecular weight polyethylene (UHMWPE). Three components comprise this modular prosthesis.
Single Arm
Intervention: Device: ProDisc™-L Total Disc Replacement (TDR)
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
March 2011
March 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Degenerative Disc Disease (DDD) in one vertebral level between L3 and S1, where a diagnosis of DDD requires:

    1. Back and/or leg (radicular) pain; and
    2. Radiographic confirmation of any one of the following by CT, MRI, discography, plain film, myelography, and/or flexion/extension films:

    i. Decreased disc height > 2 mm; ii. Scarring/thickening of annulus fibrosis; iii. Herniated nucleus pulposus; or iv. Vacuum phenomenon.

  2. Skeletally mature adult between the ages of 18 and 50 years at time of surgery.
  3. Failed at least 6 months of conservative therapy.
  4. Oswestry Low Back Pain Disability Questionnaire score ≥ 20/50 (40%) (Interpreted as moderate/severe disability).
  5. Psychosocially, mentally and physically able to fully comply with this protocol including adhering to scheduled visits, treatment plan, completing forms, and other study procedures.
  6. Plans to remain on active duty for a minimum of two (2) years.
  7. Personally signed and dated the informed consent document prior to any study-related procures indicating that the subject has been informed of all pertinent aspects of the study.

Exclusion Criteria:

  1. More than one vertebral level to be treated.
  2. The involved vertebral endplates dimensionally smaller than 34.5 mm in the medial-lateral direction and/or 27 mm in the anterior-posterior direction.
  3. Known allergy to polyethylene, cobalt chromium, or molybdenum
  4. Prior fusion surgery at any lumbar vertebral level.
  5. Clinically compromised vertebral body at the affected level due to current or past trauma.
  6. Radiographic confirmation of facet joint disease or degeneration.
  7. Lytic spondylolisthesis or spinal stenosis.
  8. Degenerative spondylolisthesis > Grade 1.
  9. Osteoporosis: A screening questionnaire for osteoporosis, SCORE (Simple Calculated Osteoporosis Risk Estimation), will be used to screen patients who require a DEXA bone mineral density measurement. If DEXA is required, exclusion will be defined as a DEXA bone density measured T score </= -2.5.
  10. Known history of Paget's disease, osteomalacia, or any other metabolic bone disease.
  11. Morbid obesity defined as a body mass index > 40 kg/m2 or weight more than 100 pounds over ideal body weight.
18 Years to 50 Years
Contact information is only displayed when the study is recruiting subjects
United States
Military ProDisc-L Study
Damon Lees, Clinical Regulatory Manager, Spine Global Regulatory & Clinical Affairs, Synthes USA HQ. Inc.
Synthes USA HQ, Inc.
Not Provided
Not Provided
Synthes USA HQ, Inc.
July 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP